Vaxxinity
VAXXVAXX · Stock Price
Historical price data
Overview
Vaxxinity (NASDAQ: VAXX) is a U.S.-based biotech firm with a mission to democratize healthcare through its proprietary Active Immunotherapy Medicine (AIM) platform. The company has achieved significant validation, including a successful Phase 3 trial for a COVID-19 booster and billions of doses commercialized in animal health, underpinning its strategy to develop long-acting, scalable therapies for large markets like Alzheimer's and hypercholesterolemia. Its core differentiator is the ability to safely break immune tolerance against self-antigens, a key hurdle in chronic disease treatment, using a synthetic, low-cost peptide approach that requires no frozen cold chain.
Technology Platform
The Active Immunotherapy Medicine (AIM) platform uses synthetic peptides to mimic biological epitopes, designed to break immune tolerance and stimulate the body's own production of durable, therapeutic antibodies against both self-antigens and foreign pathogens.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| UB-612 + BNT162b2 vaccine + ChAdOx1-S vaccine + Sinopharm BI... | COVID-19 Vaccines | Phase 3 | |
| UB-612 | Covid-19 | Phase 2/3 | |
| UB-612 + Placebo | COVID-19 | Phase 2 | |
| UB-312 + Placebo | Parkinson's Disease | Phase 1 | |
| UB-612 | COVID-19 | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Vaxxinity competes with major pharma's monoclonal antibodies and siRNA therapies in chronic diseases, and with mRNA/protein vaccines in infectious disease. Its primary differentiation is its AIM platform's ability to safely break immune tolerance for a durable, active immunization effect, coupled with a synthetic, thermostable manufacturing profile aimed at cost and access advantages.